These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33493479)

  • 1. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model.
    Errecalde J; Lifschitz A; Vecchioli G; Ceballos L; Errecalde F; Ballent M; Marín G; Daniele M; Turic E; Spitzer E; Toneguzzo F; Gold S; Krolewiecki A; Alvarez L; Lanusse C
    J Pharm Sci; 2021 Jun; 110(6):2501-2507. PubMed ID: 33493479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.
    Aref ZF; Bazeed SEES; Hassan MH; Hassan AS; Rashad A; Hassan RG; Abdelmaksoud AA
    Int J Nanomedicine; 2021; 16():4063-4072. PubMed ID: 34163159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a Topically Applied Gel Spray Formulation with Ivermectin Using a Novel Low Molecular Weight Gelling Agent, Palmitoyl-Glycine-Histidine, to Treat Scabies.
    Dahlizar S; Futaki M; Okada A; Kadhum WR; Todo H; Sugibayashi K
    Chem Pharm Bull (Tokyo); 2018; 66(3):327-333. PubMed ID: 29491265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The route of administration drastically affects ivermectin activity against small strongyles in horses.
    Saumell C; Lifschitz A; Baroni R; Fusé L; Bistoletti M; Sagües F; Bruno S; Alvarez G; Lanusse C; Alvarez L
    Vet Parasitol; 2017 Mar; 236():62-67. PubMed ID: 28288767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.
    Jermain B; Hanafin PO; Cao Y; Lifschitz A; Lanusse C; Rao GG
    J Pharm Sci; 2020 Dec; 109(12):3574-3578. PubMed ID: 32891630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the long-acting ivermectin formulation in sheep: Further insight into potential pharmacokinetic interactions.
    Ballent M; Maté ML; Dominguez P; Virkel G; Albérich M; Lespine A; Lanusse C; Lifschitz AL
    J Vet Pharmacol Ther; 2019 Mar; 42(2):189-196. PubMed ID: 30520071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivermectin systemic availability in adult volunteers treated with different oral pharmaceutical formulations.
    Ceballos L; Alvarez L; Lifschitz A; Lanusse C
    Biomed Pharmacother; 2023 Apr; 160():114391. PubMed ID: 36804122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.
    Song R; Chen X; Li B; Zhang H; Guo X; Liu Z; Zou L; Liang X; Lei C; Mao F; Sui J; Li W; Jin R
    J Med Virol; 2023 May; 95(5):e28805. PubMed ID: 37227062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2.
    Meister TL; Todt D; Brüggemann Y; Steinmann J; Banava S; Brill FHH; Steinmann J; Pfaender S; Steinmann E
    J Hosp Infect; 2022 Feb; 120():9-13. PubMed ID: 34752803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment.
    Albariqi AH; Wang Y; Chang RYK; Quan DH; Wang X; Kalfas S; Drago J; Britton WJ; Chan HK
    Int J Pharm; 2022 May; 619():121688. PubMed ID: 35314278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model.
    Bernigaud C; Fang F; Fischer K; Lespine A; Aho LS; Dreau D; Kelly A; Sutra JF; Moreau F; Lilin T; Botterel F; Guillot J; Chosidow O
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005030. PubMed ID: 27732588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma dispositions and concentrations of ivermectin in eggs following treatment of laying hens.
    Cirak VY; Aksit D; Cihan H; Gokbulut C
    N Z Vet J; 2018 May; 66(3):121-125. PubMed ID: 29378154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal sprays for treating COVID-19: a scientific note.
    Chavda VP; Baviskar KP; Vaghela DA; Raut SS; Bedse AP
    Pharmacol Rep; 2023 Apr; 75(2):249-265. PubMed ID: 36848033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle.
    Lifschitz A; Virkel G; Sallovitz J; Sutra JF; Galtier P; Alvinerie M; Lanusse C
    Vet Parasitol; 2000 Feb; 87(4):327-38. PubMed ID: 10669102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma profiles of ivermectin in horses following oral or intramuscular administration.
    Pérez R; Godoy C; Palma C; Cabezas I; Muñoz L; Rubilar L; Arboix M; Alvinerie M
    J Vet Med A Physiol Pathol Clin Med; 2003 Aug; 50(6):297-302. PubMed ID: 12887622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivermectin (3.15%) long-acting formulations in cattle: absorption pattern and pharmacokinetic considerations.
    Lifschitz A; Virkel G; Ballent M; Sallovitz J; Imperiale F; Pis A; Lanusse C
    Vet Parasitol; 2007 Jul; 147(3-4):303-10. PubMed ID: 17524559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin.
    de Melo GD; Lazarini F; Larrous F; Feige L; Kornobis E; Levallois S; Marchio A; Kergoat L; Hardy D; Cokelaer T; Pineau P; Lecuit M; Lledo PM; Changeux JP; Bourhy H
    EMBO Mol Med; 2021 Aug; 13(8):e14122. PubMed ID: 34170074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ivermectin and oxfendazole against Taenia solium cysticercosis and other parasitoses in naturally infected pigs.
    Mkupasi EM; Ngowi HA; Sikasunge CS; Leifsson PS; Johansen MV
    Acta Trop; 2013 Oct; 128(1):48-53. PubMed ID: 23806569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.
    Winchester S; John S; Jabbar K; John I
    J Infect; 2021 Aug; 83(2):237-279. PubMed ID: 33992687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2.
    Guareschi F; Del Favero E; Ricci C; Cantù L; Brandolini M; Sambri V; Nicoli S; Pescina S; D'Angelo D; Rossi I; Buttini F; Bettini R; Sonvico F
    Eur J Pharm Sci; 2024 Feb; 193():106673. PubMed ID: 38103657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.